Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,365,016
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 16,967 M
  • Annual Income, $ 5,792 M
  • 36-Month Beta 0.66
  • Price/Sales 6.22
  • Price/Cash Flow 16.82
  • Price/Book 13.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.58
  • Number of Estimates 2
  • High Estimate 0.61
  • Low Estimate 0.55
  • Prior Year 0.62
  • Growth Rate Est. (year over year) -6.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.23 +3.20%
on 10/11/18
48.60 -12.45%
on 09/25/18
-5.11 (-10.72%)
since 09/21/18
3-Month
41.23 +3.20%
on 10/11/18
51.64 -17.60%
on 07/26/18
-7.79 (-15.47%)
since 07/23/18
52-Week
41.23 +3.20%
on 10/11/18
58.37 -27.10%
on 01/23/18
-7.65 (-15.24%)
since 10/23/17

Most Recent Stories

More News
Flex Digital Health Announces Novo Nordisk as BrightInsight Customer

Flex (NASDAQ:FLEX), the Sketch-to-Scale® solutions provider that designs and builds Intelligent Products for a Connected World®, today announced a partnership with Novo Nordisk to develop digital health...

NVO : 42.22 (-2.09%)
FLEX : 11.38 (-3.07%)
Cardiovascular safety data added to Saxenda® label

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg. The label now includes some data from the landmark LEADER...

NVO : 42.22 (-2.09%)
Novo Nordisk and Sanofi brands rank best for the digital type 2 diabetes patient experience, study finds

Novo Nordisk and Sanofi lead the pack when it comes to delivering a standout online experience to U.S. patients in the crowded marketplace for type 2 diabetes treatments, a study from DRG Digital | Manhattan...

NVO : 42.22 (-2.09%)
Novo Nordisk (NVO) Faces Pricing Pressure and Competition

Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.

NVO : 42.22 (-2.09%)
MRK : 71.71 (-1.19%)
LLY : 109.33 (-2.41%)
SNY : 43.87 (-1.50%)
PFE or NVO: Which Is the Better Value Stock Right Now?

PFE vs. NVO: Which Stock Is the Better Value Option?

NVO : 42.22 (-2.09%)
PFE : 43.93 (-0.99%)
Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm

Bagsvaerd, Denmark, 15 October 2018 - Novo Nordisk A/S today announced the appointment of Ludovic Helfgott as executive vice president of Biopharm, effective 3 April 2019.

NVO : 42.22 (-2.09%)
Google, Disney and LEGO Lead the World in Corporate Responsibility

Reputation Institute (RI), the global leader in Reputation Intelligence, today announced the 2018 Global CR RepTrak(R) rankings. Google tops the ranking with the best reputation for overall corporate responsibility...

NVO : 42.22 (-2.09%)
Lilly's Novel Diabetes Candidate Shows Promise in Phase II

Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.

AZN : 39.18 (-0.79%)
NVO : 42.22 (-2.09%)
LLY : 109.33 (-2.41%)
RHHBY : 30.5200 (-0.62%)
Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies

Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.

NVO : 42.22 (-2.09%)
LLY : 109.33 (-2.41%)
NVS : 86.49 (-0.70%)
RHHBY : 30.5200 (-0.62%)
Omnipod(R) Insulin Management System Now Available for Use in Europe with Fiasp(R) Fast-Acting Insulin

Insulet Corporation(NASDAQ: PODD) (Insuletor the Company), the global leader intubeless insulin pump technology with its Omnipod(R)Insulin Management System (Omnipod System), today...

NVO : 42.22 (-2.09%)
PODD : 86.41 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 43.39
1st Resistance Point 43.25
Last Price 42.22
1st Support Level 42.98
2nd Support Level 42.85

See More

52-Week High 58.37
Fibonacci 61.8% 51.82
Fibonacci 50% 49.80
Fibonacci 38.2% 47.78
Last Price 42.22
52-Week Low 41.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar